Latanoprost 0.005% in POAG: effects on IOP and ocular blood flow.
The scope of this work was to evaluate the effect on ocular pressure and on ocular blood flow of latanoprost 0.005% eyedrops. Included in the study were 12 patients (24 eyes) with POAG, aged between 37 and 48 years, non-smokers, refractions between +/- 3D. Haemorrheological parameters within normal, not in ocular or systemic vasoactive therapy. Each patient had one eye treated with latanoprost 0.005% and the other with timolol 0.05%. The choroidal perfusion was measured by Langham's POBF system during the first day of therapy and then after 7, 15, 30, 60, 90 and 180 days. The maximum pressure decrease after the first administration of latanoprost was at the twelfth hour; after 6 months of therapy, mean IOP reduction was 32.6%. POBF values increased up to 55.8% in the first day and then settled at 22.6% at the end of the study. Timolol showed a similar pressure progress, but its haematic perfusion values were distinctly lower. In conclusion, latanoprost is efficacious in POAG therapy since it unites a positive optic nerve head perfusion effect with hypotensive efficacy.
Vetrugno
M
M
Department of Ophthalmology and Otorhinolaryngology, University of Bari.
Cantatore
F
F
Gigante
G
G
Cardia
L
L
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D001783:Blood Flow Velocity / Q000187:drug effects; D002829:Choroid / Q000098:blood supply*; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D016037:Single-Blind Method; D013999:Timolol / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome